Michael R Horsman

List of Publications by Year in Descending Order

179 papers	7,001 citations	47 h-index	77 g-index
186 ext. papers	7,696 ext. citations	3.3 avg, IF	6.05 L-index

#	Paper	IF	Citations
179	Does the combination of hyperthermia with low LET (linear energy transfer) radiation induce anti-tumor effects equivalent to those seen with high LET radiation alone?. *International Journal of Hyperthermia*, **2021**, 38, 105-110	3.7	1
178	Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions. *Seminars in Nuclear Medicine*, **2020**, 50, 562-583	5.4	13
177	Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	6
176	Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways. *Frontiers in Oncology*, **2020**, 10, 562	5.3	54
175	In vitro hypoxia responsiveness of [F] FDG and [F] FAZA retention: influence of shaking versus stagnant conditions, glass versus polystyrene substrata and cell number down-scaling. *EJNMMI Radiopharmacy and Chemistry*, **2020**, 5, 14	5.8	0
174	Proton scanning and X-ray beam irradiation induce distinct regulation of inflammatory cytokines in a preclinical mouse model. *International Journal of Radiation Biology*, **2020**, 96, 1238-1244	2.9	6
173	Hyperthermia: The Optimal Treatment to Overcome Radiation Resistant Hypoxia. *Cancers*, **2019**, 11,	6.6	83
172	Reliability of blood lactate as a measure of exercise intensity in different strains of mice during forced treadmill running. *PLoS ONE*, **2019**, 14, e0215584	3.7	10
171	Dual-tracer PET of viable tumor volume and hypoxia for identification of necrosis-containing radio-resistant Sub-volumes. *Acta Oncologica*, **2019**, 58, 1476-1482	3.2	2
170	APD-Containing Cyclolipodepsipeptides Target Mitochondrial Function in Hypoxic Cancer Cells. *Cell Chemical Biology*, **2018**, 25, 1337-1349.e12	8.2	17
169	FDG-PET reproducibility in tumor-bearing mice: comparing a traditional SUV approach with a tumor-to-brain tissue ratio approach. *Acta Oncologica*, **2017**, 56, 706-712	3.2	6
168	Relative biological effectiveness (RBE) and distal edge effects of proton radiation on early damage in vivo. *Acta Oncologica*, **2017**, 56, 1387-1391	3.2	35
167	Enhancing the radiation response of tumors but not early or late responding normal tissues using a vascular disrupting agent. *Acta Oncologica*, **2017**, 56, 1634-1638	3.2	6
166	Results from C-metformin-PET scans, tissue analysis and cellular drug-sensitivity assays questions the view that biguanides affects tumor respiration directly. *Scientific Reports*, **2017**, 7, 9436	4.9	17
165	The potential of hyperpolarized C magnetic resonance spectroscopy to monitor the effect of combretastatin based vascular disrupting agents. *Acta Oncologica*, **2017**, 56, 1626-1633	3.2	7
164	Hypoxia positron emission tomography imaging: combining information on perfusion and tracer retention to improve hypoxia specificity. *Acta Oncologica*, **2017**, 56, 1583-1590	3.2	4
163	Hypoxia as a Biomarker and for Personalized Radiation Oncology. *Recent Results in Cancer Research*, **2016**, 198, 123-42	1.5	20

162	Realistic biological approaches for improving thermoradiotherapy. *International Journal of Hyperthermia*, **2016**, 32, 14-22	3.7	9
161	Dose-Response Modifiers in Radiation Therapy **2016**, 51-62.e3		3
160	Pathophysiological Basis for the Formation of the Tumor Microenvironment. *Frontiers in Oncology*, **2016**, 6, 66	5.3	105
159	The impact of hypoxia and its modification of the outcome of radiotherapy. *Journal of Radiation Research*, **2016**, 57 Suppl 1, i90-i98	2.4	172
158	Improving efficacy of hyperthermia in oncology by exploiting biological mechanisms. *International Journal of Hyperthermia*, **2016**, 32, 446-54	3.7	70
157	Simulation of heterogeneous molecular delivery in tumours using CT reconstructions and MRI validation. *Microvascular Research*, **2016**, 108, 69-74	3.7	0
156	The usability of a 15-gene hypoxia classifier as a universal hypoxia profile in various cancer cell types. *Radiotherapy and Oncology*, **2015**, 116, 346-51	5.3	22
155	Modulation of the tumor vasculature and oxygenation to improve therapy. *Pharmacology & Therapeutics*, **2015**, 153, 107-24	13.9	70
154	Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 6974-92	3.4	17
153	Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy. *Acta Oncologica*, **2015**, 54, 1385-92	3.2	8
152	Relative biological effectiveness of carbon ions for tumor control, acute skin damage and late radiation-induced fibrosis in a mouse model. *Acta Oncologica*, **2015**, 54, 1623-30	3.2	27
151	Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation. *International Journal of Hyperthermia*, **2015**, 31, 453-9	3.7	9
150	Hyperpolarized magnetic resonance spectroscopy for assessing tumor hypoxia. *Acta Oncologica*, **2015**, 54, 1393-8	3.2	6
149	Photoelectron Spectra and Electronic Structures of the Radiosensitizer Nimorazole and Related Compounds. *Journal of Physical Chemistry A*, **2015**, 119, 9986-95	2.8	14
148	A tissue-engineered therapeutic device inhibits tumor growth in vitro and in vivo. *Acta Biomaterialia*, **2015**, 18, 21-9	10.8	15
147	Simultaneous Hypoxia and Low Extracellular pH Suppress Overall Metabolic Rate and Protein Synthesis In Vitro. *PLoS ONE*, **2015**, 10, e0134955	3.7	15
146	Uniform Combretastatin-induced Effect on Monocytes and Neutrophils in Peripheral Blood but Not in Tumors. *Anticancer Research*, **2015**, 35, 2559-64	2.3	2
145	In vivo bio-distribution and homing of endothelial outgrowth cells in a tumour model. *Nuclear Medicine and Biology*, **2014**, 41, 848-55	2.1	4

144	Accumulation of nano-sized particles in a murine model of angiogenesis. *Biochemical and Biophysical Research Communications*, **2014**, 443, 470-6	3.4	4
143	Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model. *BMC Cancer*, **2014**, 14, 903	4.8	
142	Clinical Imaging of Hypoxia. *Cancer Drug Discovery and Development*, **2014**, 179-201	0.3	
141	Formation of radical anions of radiosensitizers and related model compounds via electrospray ionization. *International Journal of Mass Spectrometry*, **2014**, 365-366, 56-63	1.9	24
140	A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models. *PLoS ONE*, **2014**, 9, e110091	3.7	5
139	Hypoxia and Radiation Therapy. *Cancer Drug Discovery and Development*, **2014**, 265-281	0.3	1
138	Hypoxia, Metastasis, and Antiangiogenic Therapies. *Cancer Drug Discovery and Development*, **2014**, 205-227	2.3	2
137	Effect of radiation on cell proliferation and tumor hypoxia in HPV-positive head and neck cancer in vivo models. *Anticancer Research*, **2014**, 34, 6297-304	2.3	13
136	Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. *Radiotherapy and Oncology*, **2013**, 108, 500-5	5.3	78
135	Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. *Acta Oncologica*, **2013**, 52, 1320-6	3.2	22
134	Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model. *Acta Oncologica*, **2013**, 52, 1730-8	3.2	17
133	The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. *Cancer Research*, **2013**, 73, 5618-24	10.1	100
132	PET imaging of tumor hypoxia using 18F-labeled pimonidazole. *Acta Oncologica*, **2013**, 52, 1300-7	3.2	20
131	Ultra-high field 1H magnetic resonance imaging approaches for acute hypoxia. *Acta Oncologica*, **2013**, 52, 1287-92	3.2	4
130	Tumour microenvironment and radiation response in sarcomas originating from tumourigenic human mesenchymal stem cells. *International Journal of Radiation Biology*, **2012**, 88, 457-65	2.9	3
129	Imaging hypoxia to improve radiotherapy outcome. *Nature Reviews Clinical Oncology*, **2012**, 9, 674-87	19.4	422
128	Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L. *European Journal of Medicinal Chemistry*, **2012**, 58, 568-72	6.8	24
127	The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries. *European Journal of Pharmacology*, **2012**, 695, 104-11	5.3	8

126	Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. *Pharmaceutics*, **2012**, 4, 563-89	6.4	31
125	Ultrahigh-field DCE-MRI of angiogenesis in a novel angiogenesis mouse model. *Journal of Magnetic Resonance Imaging*, **2012**, 35, 703-10	5.6	10
124	Tumourigenicity and radiation resistance of mesenchymal stem cells. *Acta Oncologica*, **2012**, 51, 669-79	3.2	10
123	Treatment with the vascular disrupting agent combretastatin is associated with impaired AQP2 trafficking and increased urine output. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2012**, 303, R186-98	3.2	5
122	Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging. *Clinical Cancer Research*, **2012**, 18, 6469-77	12.9	24
121	Dose-Response Modifiers in Radiation Therapy **2012**, 53-64		1
120	Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. *International Journal of Radiation Biology*, **2011**, 87, 1126-34	2.9	18
119	Inhibition of tumor lactate oxidation: consequences for the tumor microenvironment. *Radiotherapy and Oncology*, **2011**, 99, 404-11	5.3	26
118	Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance. *Radiotherapy and Oncology*, **2011**, 99, 373-8	5.3	46
117	Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study. *Radiotherapy and Oncology*, **2011**, 99, 418-23	5.3	33
116	Combretastatin-induced hypertension and the consequences for its combination with other therapies. *Vascular Pharmacology*, **2011**, 54, 13-7	5.9	15
115	In vivo identification and specificity assessment of mRNA markers of hypoxia in human and mouse tumors. *BMC Cancer*, **2011**, 11, 63	4.8	10
114	Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. *Apmis*, **2010**, 118, 585-94	3.4	27
113	Tumour perfusion and associated physiology: characterization and significance for hyperthermia. *International Journal of Hyperthermia*, **2010**, 26, 209-10	3.7	18
112	Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates. *Acta Oncologica*, **2010**, 49, 906-13	3.2	18
111	Imaging tumour physiology and vasculature to predict and assess response to heat. *International Journal of Hyperthermia*, **2010**, 26, 264-72	3.7	4
110	Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. *Acta Oncologica*, **2010**, 49, 922-33	3.2	31
109	Biodistribution of 99mTc-HYNIC-lactadherin in mice--a potential tracer for visualizing apoptosis in vivo. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2010**, 70, 209-16	2	13

108	Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. *Acta Oncologica*, **2010**, 49, 1283-7	3.2	32
107	Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro. *Acta Oncologica*, **2010**, 49, 895-905	3.2	52
106	Vascular targeted therapies in oncology. *Cell and Tissue Research*, **2009**, 335, 241-8	4.2	70
105	Size-Dependent Accumulation of PEGylated Silane-Coated Magnetic Iron Oxide Nanoparticles in Murine Tumors. *ACS Nano*, **2009**, 3, 1947-51	16.7	221
104	Proteins upregulated by mild and severe hypoxia in squamous cell carcinomas in vitro identified by proteomics. *Radiotherapy and Oncology*, **2009**, 92, 443-9	5.3	28
103	Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast?. *Radiotherapy and Oncology*, **2009**, 92, 429-36	5.3	44
102	The oxygen effect and fractionated radiotherapy **2009**, 207-216		24
101	Significance of the Tumour Microenvironment in Radiotherapy **2009**, 137-156		
100	Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. *Radiotherapy and Oncology*, **2008**, 87, 331-8	5.3	14
99	Angiogenesis and vascular targeting: relevance for hyperthermia. *International Journal of Hyperthermia*, **2008**, 24, 57-65	3.7	15
98	Segmentation of dynamic contrast enhanced magnetic resonance imaging data. *Acta Oncologica*, **2008**, 47, 1265-70	3.2	8
97	Resolution in PET hypoxia imaging: voxel size matters. *Acta Oncologica*, **2008**, 47, 1201-10	3.2	55
96	The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours. *Acta Oncologica*, **2008**, 47, 1071-6	3.2	12
95	The impact of hypoxia on the activity of lactate dehydrogenase in two different pre-clinical tumour models. *Acta Oncologica*, **2008**, 47, 941-7	3.2	18
94	Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. *European Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 35, 2294-303	8.8	88
93	Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. *International Journal of Cancer*, **2008**, 122, 2726-34	7.5	92
92	Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. *International Journal of Radiation Oncology Biology Physics*, **2008**, 70, 859-66	4	17
91	Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. *International Journal of Radiation Oncology Biology Physics*, **2008**, 70, 1202-12	4	69

90	Small-Molecule Vascular Disrupting Agents in Cancer Therapy **2008**, 297-310		2
89	Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. *Neoplasia*, **2007**, 9, 108-12	6.4	42
88	Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. *Radiotherapy and Oncology*, **2007**, 83, 389-97	5.3	71
87	Hypoxia induced expression of endogenous markers in vitro is highly influenced by pH. *Radiotherapy and Oncology*, **2007**, 83, 362-6	5.3	56
86	The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS. *Acta Oncologica*, **2006**, 45, 306-16	3.2	16
85	Radiation administered as a large single dose or in a fractionated schedule: Role of the tumour vasculature as a target for influencing response. *Acta Oncologica*, **2006**, 45, 876-80	3.2	16
84	Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. *Cancer Research*, **2006**, 66, 11520-39	10.1	211
83	Strain and tumour specific variations in the effect of hypoxia on osteopontin levels in experimental models. *Radiotherapy and Oncology*, **2006**, 80, 165-71	5.3	9
82	Tumour hypoxia - a characteristic feature with a complex molecular background. *Radiotherapy and Oncology*, **2006**, 81, 119-21	5.3	14
81	Tissue physiology and the response to heat. *International Journal of Hyperthermia*, **2006**, 22, 197-203	3.7	61
80	Combined Modality Approaches Using Vasculature-disrupting Agents **2006**, 123-136		6
79	Vasculature-targeting Therapies and Hyperthermia **2006**, 137-157		4
78	In response to Drs. van der Zee and van Rhoon. *International Journal of Radiation Oncology Biology Physics*, **2006**, 66, 634	4	
77	Current development status of small-molecule vascular disrupting agents. *Current Opinion in Investigational Drugs*, **2006**, 7, 522-8		50
76	Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. *Lancet Oncology, The*, **2005**, 6, 757-64	21.7	244
75	Influence of oxygen concentration and pH on expression of hypoxia induced genes. *Radiotherapy and Oncology*, **2005**, 76, 187-93	5.3	103
74	Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum. *International Journal of Radiation Biology*, **2005**, 81, 937-44	2.9	17
73	Intravenous administration of Gd-DTPA prior to DWI does not affect the apparent diffusion constant. *Magnetic Resonance Imaging*, **2005**, 23, 685-9	3.3	33

72	Intravascular contrast agent-enhanced MRI measuring contrast clearance and tumor blood volume and the effects of vascular modifiers in an experimental tumor. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 1208-15	4	23
71	Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode Po2 measurements in murine tumors. *International Journal of Radiation Oncology Biology Physics*, **2005**, 62, 854-61	4	45
70	Differentiation and definition of vascular-targeted therapies. *Clinical Cancer Research*, **2005**, 11, 416-20	12.9	189
69	Evaluation of anti-vascular therapy with texture analysis. *Anticancer Research*, **2005**, 25, 3399-405	2.3	16
68	Targeting the tumor vasculature: a strategy to improve radiation therapy. *Expert Review of Anticancer Therapy*, **2004**, 4, 321-7	3.5	28
67	Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2004**, 31, 513-20	8.8	74
66	Vascular-targeting therapies for treatment of malignant disease. *Cancer*, **2004**, 100, 2491-9	6.4	274
65	Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen. *Radiotherapy and Oncology*, **2004**, 70, 301-9	5.3	12
64	Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. *International Journal of Radiation Oncology Biology Physics*, **2003**, 57, 1047-55	4	57
63	Combination of vascular targeting agents with thermal or radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2002**, 54, 1518-23	4	56
62	Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing. *Acta Oncologica*, **2002**, 41, 304-12	3.2	56
61	Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy. *Neoplasia*, **2002**, 4, 263-7	6.4	12
60	Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2001**, 51, 1018-24	4	64
59	Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. *Radiation Research*, **2001**, 156, 503-9	3.1	72
58	Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. *Acta Oncologica*, **2001**, 40, 497-503	3.2	34
57	Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. *Radiotherapy and Oncology*, **2001**, 60, 155-61	5.3	100
56	Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. *Radiotherapy and Oncology*, **2000**, 57, 5-12	5.3	59
55	The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. *International Journal of Radiation Oncology Biology Physics*, **1998**, 42, 895-8	4	87

54	Relationship of hypoxia to metallothionein expression in murine tumors. *International Journal of Radiation Oncology Biology Physics*, **1998**, 42, 727-30	4	31
53	Measurement of tumor oxygenation. *International Journal of Radiation Oncology Biology Physics*, **1998**, 42, 701-4	4	75
52	The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies. *Radiotherapy and Oncology*, **1998**, 48, 143-8	5.3	22
51	The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. *Acta Oncologica*, **1998**, 37, 441-5	3.2	13
50	Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. *Radiotherapy and Oncology*, **1997**, 45, 167-74	5.3	40
49	Tolerance to nicotinamide and carbogen with radiation therapy for glioblastoma. *Radiotherapy and Oncology*, **1997**, 43, 109-10	5.3	3
48	A comparison of the physiological effects of RSU1069 and RB6145 in the SCCVII murine tumour. *Acta Oncologica*, **1996**, 35, 989-94	3.2	5
47	Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. *Seminars in Radiation Oncology*, **1996**, 6, 10-21	5.5	344
46	The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation. *Acta Oncologica*, **1995**, 34, 297-300	3.2	37
45	Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. *Acta Oncologica*, **1995**, 34, 329-34	3.2	26
44	Cytotoxic effect of tumour necrosis factor -alpha on sarcoma F cells at tumour relevant oxygen tensions. *Acta Oncologica*, **1995**, 34, 423-7	3.2	10
43	The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma. *Acta Oncologica*, **1995**, 34, 443-6	3.2	7
42	Reoxygenation in a C3H mouse mammary carcinoma. The importance of chronic rather than acute hypoxia. *Acta Oncologica*, **1995**, 34, 325-8	3.2	8
41	Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. *Acta Oncologica*, **1995**, 34, 571-87	3.2	117
40	Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. *Acta Oncologica*, **1994**, 33, 371-6	3.2	57
39	Ischaemia induced cell death in tumors: importance of temperature and pH. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 499-503	4	20
38	Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 439-42	4	68
37	Effect of carbon monoxide breathing on hypoxia and radiation response in the SCCVII tumor in vivo. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 449-54	4	26

36	Importance of nicotinamide dose on blood pressure changes in mice and humans. *International Journal of Radiation Oncology Biology Physics*, **1994**, 29, 455-8	4	9
35	The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. *Radiotherapy and Oncology*, **1994**, 31, 117-22	5.3	36
34	The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment. *Advances in Experimental Medicine and Biology*, **1994**, 361, 635-42	3.6	7
33	Tumour radiosensitization by nicotinamide: is it the result of an improvement in tumour oxygenation?. *Advances in Experimental Medicine and Biology*, **1994**, 345, 403-9	3.6	5
32	Measurement of pO2 in a murine tumour and its correlation with hypoxic fraction. *Advances in Experimental Medicine and Biology*, **1994**, 345, 493-500	3.6	6
31	Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. *Radiotherapy and Oncology*, **1993**, 27, 131-9	5.3	80
30	Relationship between radiobiological hypoxia and direct estimates of tumour oxygenation in a mouse tumour model. *Radiotherapy and Oncology*, **1993**, 28, 69-71	5.3	67
29	Reduction of cisplatinum-induced renal toxicity in mice by tetrahydroindazolonecarboxylic acid (HIDA) [corrected]. *Acta Oncologica*, **1993**, 32, 53-6	3.2	2
28	Cisplatin and hyperthermia treatment of a C3H mammary carcinoma in vivo. Importance of sequence, interval, drug dose, and temperature. *Acta Oncologica*, **1992**, 31, 347-51	3.2	15
27	Carbogen and nicotinamide: expectations too high? (response to J. Martin Brown). *Radiotherapy and Oncology*, **1992**, 24, 121-2	5.3	9
26	Overcoming tumour radiation resistance resulting from acute hypoxia. *European Journal of Cancer*, **1992**, 28A, 2084-5	7.5	7
25	Overcoming tumour radiation resistance resulting from acute hypoxia. *European Journal of Cancer*, **1992**, 28A, 717-8	7.5	23
24	BW12C-induced changes in haemoglobin-oxygen affinity in mice and its influence on the radiation response of a C3H mouse mammary carcinoma. *Radiotherapy and Oncology*, **1992**, 25, 43-8	5.3	6
23	Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice. *International Journal of Radiation Oncology Biology Physics*, **1992**, 22, 451-4	4	34
22	Relationship between the hydralazine-induced changes in murine tumor blood supply and mouse blood pressure. *International Journal of Radiation Oncology Biology Physics*, **1992**, 22, 455-8	4	39
21	Tumor blood flow changes induced by chemical modifiers of radiation response. *International Journal of Radiation Oncology Biology Physics*, **1992**, 22, 459-62	4	24
20	Improving the radiation response in a C3H mouse mammary carcinoma by normobaric oxygen or carbogen breathing. *International Journal of Radiation Oncology Biology Physics*, **1992**, 22, 415-9	4	68
19	Influence of carboxyhemoglobin level on tumor growth, blood flow, and radiation response in an experimental model. *International Journal of Radiation Oncology Biology Physics*, **1992**, 22, 421-4	4	36

18	INTERACTION OF HYPERTHERMIA AND RADIATION IN SOLID TUMOURS IN VIVO **1992**, 1033-1040		
17	The measurement of radiosensitizer-induced changes in mouse tumor metabolism by 31P magnetic resonance spectroscopy. *International Journal of Radiation Oncology Biology Physics*, **1991**, 20, 291-4	4	20
16	Drug induced perturbations in tumor blood flow: therapeutic potential and possible limitations. *Radiotherapy and Oncology*, **1991**, 20 Suppl 1, 93-101	5.3	23
15	The use of blood flow modifiers to improve the treatment response of solid tumors. *Radiotherapy and Oncology*, **1991**, 20 Suppl 1, 47-52	5.3	23
14	The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. *Radiotherapy and Oncology*, **1990**, 18, 49-57	5.3	56
13	Improved Treatment of Tumours in vivo by Combining the Bioreductive Drug RSU-1069, Hydralazine and Hyperthermia **1990**, 193-202		1
12	Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. *International Journal of Hyperthermia*, **1989**, 5, 123-36	3.7	96
11	Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status. *International Journal of Radiation Oncology Biology Physics*, **1989**, 16, 1273-6	4	40
10	Misonidazole chemosensitization of EMT6 spheroids to melphalan. *Radiotherapy and Oncology*, **1989**, 15, 103-14	5.3	4
9	Tumor Radiosensitization by Nicotinamide: A Result of Improved Perfusion and Oxygenation. *Radiation Research*, **1989**, 118, 139	3.1	96
8	Mechanism of action of the selective tumor radiosensitizer nicotinamide. *International Journal of Radiation Oncology Biology Physics*, **1988**, 15, 685-90	4	69
7	The effect of artificially induced hyperglycemia on the radiation response of the Lewis lung and EMT6 tumor models. *International Journal of Radiation Biology*, **1988**, 54, 803-11	2.9	2
6	Radiosensitization by Nicotinamide in Vivo: A Greater Enhancement of Tumor Damage Compared to That of Normal Tissues. *Radiation Research*, **1987**, 109, 479	3.1	82
5	The effects of purine nucleoside analogs on the response of the RIF-1 tumor to melphalan in vivo. *International Journal of Radiation Oncology Biology Physics*, **1986**, 12, 801-6	4	2
4	Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. *International Journal of Radiation Oncology Biology Physics*, **1986**, 12, 1307-10	4	43
3	Modification of alkylating agent cytotoxicity by cisplatin. *International Journal of Radiation Oncology Biology Physics*, **1984**, 10, 1669-73	4	2
2	The effect of misonidazole on the cytotoxicity and repair of potentially lethal damage from alkylating agents in vitro. *International Journal of Radiation Oncology Biology Physics*, **1982**, 8, 761-5	4	6
1	Impact on Radiotherapy353-376		1